Cyclerion Therapeutics, Inc.
CYCN
$1.53
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.86M | 2.17M | 2.08M | 2.00M | 194.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.86M | 2.17M | 2.08M | 2.00M | 194.00K |
| Cost of Revenue | 210.00K | -57.00K | -8.00K | 0.00 | -1.26M |
| Gross Profit | 2.65M | 2.23M | 2.09M | 2.00M | 1.46M |
| SG&A Expenses | 5.99M | 5.70M | 5.27M | 5.34M | 6.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.49M | 5.93M | 5.55M | 5.63M | 6.12M |
| Operating Income | -3.63M | -3.76M | -3.47M | -3.63M | -5.93M |
| Income Before Tax | -2.20M | -1.95M | -2.94M | -3.06M | -5.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.20 | -1.95 | -2.94 | -3.06 | -5.28 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 0.00 |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.20M | -1.95M | -2.94M | -3.06M | -5.28M |
| EBIT | -3.63M | -3.76M | -3.47M | -3.63M | -5.93M |
| EBITDA | -- | -- | -- | -- | -1.78M |
| EPS Basic | -0.76 | -0.74 | -1.16 | -1.22 | -2.12 |
| Normalized Basic EPS | -0.74 | -0.73 | -0.73 | -0.76 | -1.33 |
| EPS Diluted | -0.76 | -0.74 | -1.16 | -1.22 | -2.12 |
| Normalized Diluted EPS | -0.74 | -0.73 | -0.73 | -0.76 | -1.33 |
| Average Basic Shares Outstanding | 11.39M | 10.70M | 10.13M | 10.07M | 9.99M |
| Average Diluted Shares Outstanding | 11.39M | 10.70M | 10.13M | 10.07M | 9.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |